Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19 was set up early in the pandemic. Its aim was to get treatments for COVID-19 to patients quickly and safely as part of temporary emergency pandemic arrangements.
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
You can read more about NICE’s guidance and advice on COVID-19.
About RAPID C-19
RAPID C-19 monitored emerging trial evidence on the clinical effectiveness of potential COVID-19 treatments during the pandemic. This meant that evidence could be assessed rapidly and COVID‑19 treatments made available to patients if the evidence of benefit was strong.
RAPID C-19 was a collaboration between NICE and these organisations:
NHS England
Medicines and Healthcare products Regulatory Agency
National Institute for Health and Care Research
Scottish Medicines Consortium (Healthcare Improvement Scotland)
All Wales Therapeutics and Toxicology Centre
All Wales Medicines Strategy Group
Department of Health in Northern Ireland
Antivirals and Therapeutics Task Force at the Department of Health and Social Care.